Nuvation Bio Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Nuvation Bio Inc. on December 14, 2023, covering events occurring on December 11 and December 12, 2023. The company is a Delaware corporation with its principal executive offices in New York, NY, and its Class A Common Stock trades on the New York Stock Exchange under the symbol "NUVB."
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial statements or performance metrics.
Material Changes
The primary material change reported is the departure of a director:
- Oleg Nodelman notified the Company of his intent to resign as a member of the Board of Directors on December 11, 2023.
- His resignation became effective immediately upon delivery of a letter to the Board on December 12, 2023.
- Mr. Nodelman was not a member of any Board committees.
- The Company stated the resignation is not the result of any disagreement with the Company or its subsidiaries regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, outlook, management commentary on financial performance, or specific risk factors. The only commentary provided is a statement of thanks for Mr. Nodelman's service and confirmation that his departure was amicable.
Key Facts for Investor Verification
- Verify the current composition of the Board of Directors following Mr. Nodelman's immediate resignation.
- Confirm whether the Company intends to appoint a replacement director to fill the vacancy.
- Review the attached resignation letter (Exhibit 17.1) for any additional context not summarized in the main text.